A new study shows that gold nanoparticles injected into the retina can restore vision in mice with retinal degeneration, offering a less invasive alternative to current retinal prostheses.

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...

Discover how the genetics behind your eye color connects to various health conditions, from melanoma risk to pain ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

In older patients undergoing surgery, preoperative macular thickness may be a marker for vulnerability to developing postoperative delirium.

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease ...

Age-related macular degeneration (AMD), the leading cause of adult blindness, affects nearly half of Oklahomans over age 80.

Age-related macular degeneration begins with weakening of retinal pigment epithelium cells (RPEs), a layer of cells that support the retina's photoreceptors. When degeneration occurs, the affected ...